Drug intelligence / Profile preview

5-[(3R)-3-(5-methoxy-2',6'-dimethylbiphenyl-3-yl)but-1-yn-1-yl]-6-methylpyrimidine-2,4-diamine

Development stage
Unknown
Modality
Small Molecules
01

Overview

This compound is a small molecule experimental drug with molecular formula C24H26N4O and molecular weight approximately 386.49 g/mol. It is structurally characterized by a biphenyl moiety substituted with methoxy and dimethyl groups linked via a butynyl chain to a methyl-substituted pyrimidine diamine core. The drug acts as an inhibitor targeting dihydrofolate reductase (DHFR), specifically studied in the context of Candida glabrata fungal infections where it selectively inhibits the fungal enzyme over human DHFR. This mechanism disrupts folate metabolism critical for DNA synthesis in fungi, making it an antifolate agent with potential antifungal activity. The compound was developed for probing hydrophobic pockets in DHFR to enhance selectivity and potency against resistant fungal strains[7][10]. No marketed brand names or approved indications are currently available; it remains experimental[2].

Other names
(R)-5-(3-(5-methoxy - 2',6'-dimethylbiphenyl - 3 - yl)but - 1 - ynyl) - 6 - methylpyrimidine - 2,4-diamine53V
02

Targets

DHFR (Dihydrofolate reductase)

Beyond the preview

Go deeper on 5-[(3R)-3-(5-methoxy-2',6'-dimethylbiphenyl-3-yl)but-1-yn-1-yl]-6-methylpyrimidine-2,4-diamine.

Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.

Clinical trials

Full profile access

Follow clinical development from study design and recruitment through results.

  • Trial phase
  • Status
  • Readouts

Indications & development

Full profile access

Explore development by indication, patient population, and geography.

  • Indications
  • Development status
  • Countries

Licensing & deals

Full profile access

Trace asset ownership, licensing agreements, and commercial partnerships.

  • Partners
  • Deal terms
  • Milestones

Patents & exclusivity

Full profile access

Explore the patent landscape and regulatory exclusivity around an asset.

  • Patents
  • Expiration dates
  • Exclusivity

Competitive landscape

Full profile access

Compare development programs by target, modality, and indication.

  • Competing assets
  • Targets
  • Development stage

Research & analysis

Full profile access

Connect source evidence and development news to your research questions.

  • Publications
  • News
  • Analysis

Bring the full picture into focus.

See how Gosset can support your research on 5-[(3R)-3-(5-methoxy-2',6'-dimethylbiphenyl-3-yl)but-1-yn-1-yl]-6-methylpyrimidine-2,4-diamine.

Explore the full profile

Gosset Free

Get started with Gosset.

Enter your work email and we’ll be in touch with next steps.

Work email preferred.

Book a call